eXoZymes (NASDAQ:EXOZ) Stock Price Down 1.7% – Here’s Why

eXoZymes Inc. (NASDAQ:EXOZ) traded down 1.7% during mid-day trading on Monday . The company traded as low as $9.49 and last traded at $9.49. 815 shares changed hands during trading, a decline of 83% from the average session volume of 4,672 shares. The stock had previously closed at $9.65.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of eXoZymes in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

eXoZymes Stock Performance

The company has a debt-to-equity ratio of 0.01, a current ratio of 4.53 and a quick ratio of 4.53. The company has a market cap of $79.62 million, a price-to-earnings ratio of -12.32 and a beta of 2.38. The stock has a 50-day moving average price of $13.58 and a 200 day moving average price of $12.15.

eXoZymes (NASDAQ:EXOZ) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.27) earnings per share (EPS) for the quarter.

eXoZymes Company Profile

eXoZymes, Inc develops, manufactures and supplies a range of enzymes and reagents designed for molecular biology research and diagnostic applications. The company’s enzyme engineering platform underpins a portfolio of products aimed at supporting nucleic acid purification, amplification and analysis workflows.

Key offerings from eXoZymes include magnetic bead–based nucleic acid extraction kits, DNA polymerases, reverse transcriptases, proteases and custom enzyme services. In addition, the company provides molecular diagnostic test kits designed for pathogen detection, leveraging scalable production processes and quality systems aligned with regulatory standards.

eXoZymes serves academic research institutions, biotechnology and pharmaceutical companies, and clinical diagnostic laboratories worldwide.